Petersen Anne E, Tabbers Merit, Benninga Marc A, Derikx Joep P M, Gorter Ramon R, de Jong Justin R
Department of Pediatric Surgery, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Location AMC, Mailbox H7-270, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, The Netherlands.
Pediatr Surg Int. 2025 Apr 18;41(1):119. doi: 10.1007/s00383-025-06010-0.
This study aimed to evaluate the clinical outcomes of subtotal colectomy with ileorectal anastomosis (SCIRA) as an alternative treatment strategy for patients with pediatric intestinal pseudo-obstruction (PIPO) who experienced frequent enterostomy-related complications.
This retrospective observational study included PIPO patients who underwent SCIRA at our tertiary referral center between 2018 and 2023. Main outcomes were postoperative complications, surgical reinterventions, and the need for enterostomy replacement.
Five patients underwent SCIRA, including four males and one female, at a median age of 14 years (range 6-20). Before SCIRA, all patients had an enterostomy and a history of multiple enterostomy-related complications, requiring a median of nine surgical reinterventions (range 2-13). After SCIRA, the median number of complications was 1 (range 0-2), and the median number of surgical reinterventions was 1 (range 0-2). None of the patients required replacement of their enterostomy. Median follow-up duration was 49 months (range 32-58).
Following SCIRA, a low number of complications and reinterventions was observed, indicating that SCIRA may be a viable option for PIPO patients with frequent enterostomy-related complications. This approach may help to reduce the need for multiple surgical procedures in this challenging patient population.
本研究旨在评估回肠直肠吻合术式的次全结肠切除术(SCIRA)作为小儿肠假性梗阻(PIPO)且频繁发生肠造口相关并发症患者的替代治疗策略的临床疗效。
这项回顾性观察性研究纳入了2018年至2023年期间在我们的三级转诊中心接受SCIRA的PIPO患者。主要结局指标为术后并发症、手术再次干预以及更换肠造口的必要性。
5例患者接受了SCIRA,其中4例男性,1例女性,中位年龄14岁(范围6 - 20岁)。在接受SCIRA之前,所有患者均有肠造口且有多次肠造口相关并发症史,中位手术再次干预次数为9次(范围2 - 13次)。SCIRA术后,并发症的中位数量为1(范围0 - 2),手术再次干预的中位数量为1(范围0 - 2)。所有患者均无需更换肠造口。中位随访时间为49个月(范围32 - 58个月)。
SCIRA术后观察到的并发症和再次干预次数较少,表明SCIRA可能是患有频繁肠造口相关并发症的PIPO患者的可行选择。这种方法可能有助于减少这一具有挑战性的患者群体进行多次外科手术的需求。